Full Description
This volume reviews the new potential treatments and research in the area of Alzheimer's disease. Special attention is given to international developments in all fields relevant to new drug development. Topics discussed include: progress in the international harmonization of drug development guidelines for dementia drugs; bioethics and law; development of rating instruments; behavioural treatments; and the activities of the Reagan Foundation. The text integrates basic and clinical research findings, and provides evaluation of new approaches to therapy by world leaders in the field. The potential benefit for Alzheimer patients and families resulting from these research programmes, from molecular biology to clinical pharmacology, is reviewed and evaluated.
Contents
Part 1 Pathological basis of therapy in Alzheimer's disease: criteria for diagnosis of Alzheimer's disease; neuropathology of Alzheimer's disease; cell death - excitotoxins, apoptosis and hypometabolism. Part 2 The cholinergic system in brain: treatment of Alzheimer disease; cholinesterase inhibitors in Alzheimer disease treatment. Part 3 Nicotinic and muscarnic cholinergic agonists: nicotinic agonists; the potential for anti-inflammatory therapy. Part 4 Development of new therapies in Alzheimer's disease: design of clinical trials; SPECT and PET. Part 5 Social issues in Alzheimer's disease: legal and ethical issues; socio-economic aspects of Alzheimer disease treatment.
